Understanding the targets and mechanisms of human immunity to malaria caused by
Plasmodium falciparum is crucial for advancing effective vaccines and developing tools for …

Numerous efforts to understand the functional roles of antibodies demonstrated that they can
protect against malaria. However, it is unclear which antibody responses are the best …

Abstract Background Virus-like particles (VLPs) represent a significant advance in the
development of subunit vaccines, combining high safety and efficacy. Their particulate …

Malaria is a major global health problem. Pregnant women are susceptible to infection
regardless of previously acquired immunity. Placental malaria is caused by parasites …

Pregnancy-associated malaria (PAM) is a serious consequence of sequestration of
Plasmodium falciparum-parasitized erythrocytes (PE) in the placenta through adhesion to …

After more than 50 years of intensive research and development, only one malaria vaccine
candidate,“RTS, S,” has progressed to Phase 3 clinical trials. Despite only partial efficacy …

Placental malaria is caused by Plasmodium falciparum–infected erythrocytes that bind to
placental tissue. Binding is mediated by VAR2CSA, a parasite antigen coded by the var …

Placental malaria (PM) due to Plasmodium falciparum is a major cause of maternal, fetal
and infant mortality, but the mechanisms of pathogenesis and protective immunity are …

Plasmodium falciparum malaria remains one of the world's leading causes of human
suffering and poverty. Each year, the disease takes 1–3 million lives, mainly in sub-Saharan …

Placental accumulation of Plasmodium falciparum infected erythrocytes results in maternal
anemia, low birth weight, and pregnancy loss. The parasite protein VAR2CSA facilitates the …